Treating Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Ovarian Cancer:  The Oval Study: A Randomized, Controlled, Double-Arm, Double Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Women with platinum resistant ovarian cancer who have a measurable disease and have received 5 or less previous lines of therapy may be eligible to participate in this study. This treatment, which will assess the combination of the study drug, VB-11, and paclitaxel in patients with platinum resistant ovarian cancer, will be led by Dr. Joshua Cohen and his dynamic research team from the UCLA Department of Obstetrics and Gynecology

Participants must meet the following criteria:

1. Female
2. Age 18+
3. Willingness to provide Informed Consent
4. CT confirmed progressive disease
   • Confirmed platinum-resistant disease within 90 to 180 days from completion of a minimum of 4 platinum therapy cycles
   • Confirmed platinum-refractory disease defined during platinum therapy or up to 90 days from last administered platinum therapy dose

If you've answered yes to all of the above questions, please

Email: obgynresearch@mednet.ucla.edu or Call: 310-267-4331.

Patients will be stratified by the following:

• Number of prior lines of chemotherapy (< 3 vs. ≥ 3)
• Prior antiangiogenic therapy (yes vs. no)
• Platinum refractory status (refractory vs. non-refractory)

All participants enrolled in the study will undergo the following testing:

• Physical Exam
• Blood Sample Collection
• CT Tumor Assessment
• Ascites Aspiration
• Questionnaires

Once in the study, during the 1^stvisit, participants will be randomized (like drawing numbers from a hat) to one of the 2 treatment groups (study drug + paclitaxel or placebo + paclitaxel). As this is a placebo-controlled study, please note that you may receive inactive medications.

UCLA Protocol ID: IRB# 19-001886.

Please call (310) 267-4331 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.